Exciting Developments in Lung Tumor Treatment with Aliya® Technology
A six-month clinical study reveals the effectiveness of Aliya® Pulsed Electric Field Ablation in lung cancer patients.
Galvanize Therapeutics, Inc., a leading company in medical technology, has made headlines with its innovative Aliya® Pulsed Electric Field (PEF) therapy. The latest findings from the AFFINITY clinical trial indicate positive results for patients suffering from stage IV non-small cell lung cancer or lung metastasis. The publication of these results in the medical journal Cancers underscores the promising potential of this innovative approach.
A Closer Look at the AFFINITY Clinical Trial
The AFFINITY trial is meticulously designed as a prospective, non-randomized, open-label study exploring the safety and feasibility of the Aliya PEF ablation treatment. Within this study, 28 patients were monitored after receiving lung tumor ablation followed by standard-of-care treatments as deemed necessary by their healthcare team.
Key Findings from the Trial
The trial's results were striking. Notably, Aliya PEF ablation was deemed safe even when performed at the time of diagnostic biopsy, allowing for the continuation of additional cancer therapies without delay. Among the patients who underwent this innovative treatment, the local control rates of ablated tumors were impressive at 94% for those receiving concurrent therapy, while 100% among patients who did not require additional treatment. Moreover, there is compelling evidence to suggest that the Aliya PEF approach may trigger an immune response beneficial for those with advanced lung cancer.
Expert Insights and Future Implications
According to Dr. Michael A. Pritchett, an interventional pulmonologist involved in the trial, "These results provide hopeful evidence that Aliya PEF treatment can effectively control local tumors in patients diagnosed with advanced disease. Furthermore, we are beginning to see signs that this method might also stimulate systemic immune responses, presenting a valuable opportunity for integration with immunotherapy and potentially enhancing treatment outcomes for patients."
Analysis of Results from Six-Month Follow-Up
After six months, several key observations were noted from the AFFINITY trial:
- Safety First: The procedure was remarkably successful in 100% of participants. The Aliya PEF ablation was well-tolerated, including cases involving bilateral ablations. There was only one serious adverse event related to a procedure, a pneumothorax, which resolved without complications.
- Local Control Rates: A significant 96% of the patients achieved local control of tumors, while every individual who received the ablation alone (12 patients) successfully controlled their lesions without the need for additional systemic treatment.
- Immune Activation: Among those receiving only Aliya PEF ablation, a notable immune response was observed, activating both adaptive and innate immune systems, aligning with the mechanisms observed in cancer immunotherapy.
Doug Godshall, the CEO of Galvanize Therapeutics, expressed his enthusiasm regarding the findings. "We are committed to enhancing the lives of cancer patients through our clinical partnerships. The AFFINITY results amplify our confidence in the Aliya PEF technology and the potential it holds for local ablation while also stimulating a beneficial immune response."
What Makes Aliya PEF Unique?
Unlike conventional methods of thermal ablation, Aliya employs a unique process utilizing short bursts of high-voltage electric pulses to induce cell death, sparing surrounding healthy tissue. This cutting-edge treatment can be administered through minimally invasive techniques with the INUMI™ Flex needle. To date, Aliya has been utilized in over 2,000 treatments in the United States.
About Galvanize Therapeutics
Galvanize Therapeutics strives to be a pioneer in medical technology innovations aimed at treating various diseases, including solid tumors and chronic lung conditions. The company is headquartered in Redwood City, California, focusing on developing and commercializing the revolutionary Aliya® PEF energy platform across the United States.
Frequently Asked Questions
What is Aliya® Pulsed Electric Field Ablation?
Aliya® PEF Ablation is a medical procedure using high-voltage electrical pulses to destroy cancer cells while preserving surrounding tissue.
What were the main findings of the AFFINITY trial?
The trial demonstrated high local control rates of lung tumors and suggested potential immune system activation in patients.
How safe is the Aliya PEF ablation procedure?
It was reported that 100% of patients tolerated the procedure well, with only one serious adverse event noted.
Who can benefit from Aliya PEF therapy?
This therapy is designed for patients with stage IV non-small cell lung cancer or lung metastasis, especially those who are not surgical candidates.
Where can Aliya PEF therapy be received?
Currently, Aliya PEF is FDA cleared for soft tissue surgical ablation and is being utilized across clinical settings in the United States.
